Clinical trials: Docetaxel
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC
This is a randomized, open-label, superiority, multicenter clinical trial for patients with early or locally advanced (T≥2cm, N0-3, M0) HER2-positive breast cancer.
- Trial name
- NCT07797218
- Testing
- Docetaxel, Pyrotinib, Trastuzumab (Herceptin)
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Non-small Cell Lung Cancer Metastatic
A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the effects of ramucirumab in combination with docetaxel in participants with Stage IV non-small cell lung cancer who have had disease progression during or after one prior first-line…
- Trial name
- NCT01703091
- Testing
- Ramucirumab, Docetaxel
- Where
- 15 sites in Japan
- Volunteers
- 197 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors
CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors
A5301005 is a phase 1 study in patients with solid tumors which is testing the safety and tolerability of adding targeted agents to a standard chemotherapy.
- Trial name
- NCT00949624
- Testing
- CP-868,596, Docetaxel, AG-013736
- Where
- 2 sites in United States, Australia
- Volunteers
- 50 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Metastatic Breast Cancer
Biweekly Docetaxel in Patients With Metastatic Breast Cancer.
There is clinical benefit of docetaxel administered to patients who have progressed to 3 or more lines of chemotherapy including prior exposure to paclitaxel or docetaxel; using docetaxel in metastatic stage breast cancer…
- Trial name
- NCT02041351
- Testing
- Docetaxel
- Where
- 2 sites in Mexico
- Volunteers
- 17 people
- Sponsor
- Centro Universitario contra el Cáncer
IO-resistant sqNSCLC
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
Lung cancer is one of the most common forms of cancer. One common type is non-small cell lung cancer (NSCLC). NSCLC happens when abnormal cells in the lungs grow too fast. This can stop the lungs from working normally.
- Trial name
- MarsLight-11 (NCT07217301)
- Testing
- TAK-928, Control Arm
- Where
- 46 sites in United States, China and 1 more
- Volunteers
- 600 people
- Sponsor
- Takeda
Neoplasms, Prostatic Neoplasms
XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer
This is a randomized, open-label, multi-center study comparing the safety and efficacy of XRP6258 plus prednisone to mitoxantrone plus prednisone in the treatment of hormone refractory metastatic prostate cancer previously…
- Trial name
- TROPIC (NCT00417079)
- Testing
- cabazitaxel (XRP6258) (RPR116258), mitoxantrone, prednisone
- Where
- 26 sites in United States, Argentina and 24 more
- Volunteers
- 755 people
- Sponsor
- Sanofi
Non-Small Cell Lung Cancer
Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer
The goal of this clinical research study is to evaluate the effectiveness of Avastin® in combination with docetaxel and carboplatin in the treatment of lung cancer. The safety of this combination will also be studied.
- Trial name
- NCT00271505
- Testing
- Bevacizumab (Avastin), Carboplatin, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer
The main purpose of this study is to find out what effects taking the drug bevacizumab together with two chemotherapeutic agents, docetaxel and cyclophosphamide followed by doxorubicin alone before surgery will on breast cancer.
- Trial name
- NCT00203502
- Testing
- Bevacizumab, Cyclophosphamide, Docetaxel
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Pulmonary Neoplasms
Study of Preoperative Docetaxel or Cisplatin (CDDP) + Docetaxel for C-stage IB-II Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the safety and efficacy of the preoperative docetaxel and docetaxel-cisplatin combination in c-stage IB/II NSCLC, and select the optimal preoperative therapy for phase III trials.
- Trial name
- NCT00132639
- Testing
- Preoperative docetaxel-cisplatin combination chemotherapy, Preoperative docetaxel monotherapy
- Where
- Japan
- Volunteers
- 80 people
- Sponsor
- Haruhiko Fukuda
Breast Neoplasms
AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer
The primary purpose of the study is to determine the time to progression of the combination of study drug (AG-013736) and docetaxel versus docetaxel alone in patients who have not received prior chemotherapy for metastatic breast…
- Trial name
- NCT00076024
- Testing
- Docetaxel, AG-013736 (axitinib)
- Where
- 54 sites in United States, Canada and 6 more
- Volunteers
- 174 people
- Sponsor
- Pfizer
Ovarian Carcinoma
A Phase I Study of Intraperitoneal Hyperthermic Docetaxel
The primary objective is to assess the maximum tolerated dose of docetaxel administered intraperitoneally with heat at the time of second-look surgery in patients with stage II/III ovarian carcinoma.
- Trial name
- IP (NCT00474669)
- Testing
- docetaxel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Louisville
Liver Injury, Drug-Induced
Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury
The most common toxicity of TP (docetaxel and cisplatin) chemotherapy is chemotherapy-induced liver injury. However, patients don't always experience same chemotherapy-induced liver injury for the same drugs.
- Trial name
- NCT03069820
- Testing
- docetaxel and cisplatin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer
This phase I/II trial studies the side effects and best dose of 6,8-bis(benzylthio)octanoic acid (CPI-613) when given together with docetaxel and to see how well they work in treating patients with stage IIIB or IV non-small cell…
- Trial name
- NCT03370159
- Testing
- 6,8-Bis(benzylthio)octanoic Acid, Docetaxel, Pharmacological Study
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
NSCLC (Advanced Non-small Cell Lung Cancer)
A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）
This study aims to evaluate the safety and efficacy of SCTB41 combined with docetaxel in patients with previously treated non-small cell lung cancer. The Phase II part of this study is an open-label, multicenter clinical trial.
- Trial name
- NCT07609251
- Testing
- SCTB41, docetaxel
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sinocelltech Ltd.
Adrenocortical Carcinoma
Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma
The trial is a phase II trial in adrenocortical carcinoma (ACC), a rare malignancy with poor prognosis. It will provide results leading to the establishment of the effect of the included drugs.
- Trial name
- NCT00324012
- Testing
- cisplatin, taxotere
- Where
- Denmark
- Volunteers
- 19 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Breast Cancer
Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
RATIONALE: Dose-dense scheduling with (peg)filgrastim support may improve the clinical and pathologic complete response rate (pCR) and safety profile of single agent neoadjuvant docetaxel therapy.
- Trial name
- NCT00343512
- Testing
- docetaxel, protein expression analysis, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer, Neutropenia
Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
This is a randomized open label dose finding study to evaluate the efficacy and safety of F-627 on women with Stage I-IV breast cancer receiving chemotherapy treatment.
- Trial name
- NCT01648322
- Testing
- F-627, Neulasta® (pegfilgrastim)
- Where
- United States
- Volunteers
- 232 people
- Sponsor
- EVIVE Biotechnology
Breast Cancer
Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer
After a core biopsy of the tumor is obtained, patients with locally advanced breast cancer are randomized to receive 4 cycles of full dose doxorubicin (75 mg/m2 e3w) or docetaxel (100 mg/m2 e3w).
- Trial name
- NCT00123929
- Testing
- docetaxel, doxorubicin
- Where
- Spain
- Volunteers
- 250 people
- Sponsor
- Hospital San Carlos, Madrid
Squamous Cell Carcinoma, Head and Neck Cancer
Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma
Whether low-dose radiation in addition to Taxotere and Erbitux improves the response rate of patients with recurrent unresectable head and neck squamous cell carcinoma.
- Conditions
- Squamous Cell Carcinoma, Head and Neck Cancer, Recurrent Disease
- Trial name
- NCT01794845
- Testing
- Erbitux, Taxotere, Low Dose Fractionated Radiation Therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Miami
Head and Neck Cancer
Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck
Recent progress in treatment of recurrent/metastatic SCCHN has been made with the introduction of the taxanes. Docetaxel as a single agent has a response rate of 22-42% and 17% in patients with recurrent disease.
- Trial name
- NCT00216138
- Testing
- Docetaxel, Capecitabine, Premedication
- Where
- 18 sites in United States
- Volunteers
- 19 people
- Sponsor
- Hoosier Cancer Research Network